Back

Circulating Amyloid beta 1-40 is independently associated with statin treatment and LDL cholesterol reduction: a prospective cohort study

31 August 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Lipoproteins and cardiovascular risk Lipids ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Evmorfia Aivalioti

National & Kapodistrian University of Athens Medical School, Athens (Greece)

7 More presentations in this session

Presentation thumbnail
Sex-specific guideline target value attainment and prognostic value of low-density lipoprotein cholesterol in tertiary care
Ms K. Rumora (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Factors influencing low-density-lipoprotein cholesterol after acute coronary syndrome and effectiveness of intensive teleconsultation monitoring, the teleobjectif cohort study
Doctor A. Lemaitre (Caen, FR)
Abstract Slides Video
Presentation thumbnail
Remnant cholesterol, clinical characteristics and mortality in 41.767 patients from LIPIDOGRAM 2004-2015 studies - the factor analysis for mixed data cluster analysis
Professor M. Banach (Lodz, PL)
Abstract Slides Video
Presentation thumbnail
Relationship of cumulative low-density lipoprotein cholesterol with atherosclerosis
Doctor T. Yamaji (Hiroshima, JP)
Abstract Slides Video
Presentation thumbnail
Effects of Chios Mastiha essential oil on cholesterol levels of healthy volunteers: a prospective, randomized, placebo-controlled study.
Doctor D. Afendoulis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Lipoproteins and cardiovascular risk

The Event

Event poster

ESC Congress 2024

31 August 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Plasma levels of amyloid beta 1-40 are associated with ultrasonographic morphological characteristics related with carotid plaque vulnerability in individuals without cardiovascular disease
thumbnail
Congress Presentation
A meta analysis of effects of high-intensity statin and pcsk-9 inhibitor therapies on coronary plaque burden
thumbnail
Congress Presentation
Amyloid beta, a marker of vascular aging and cardiovascular disease, is associated with accelerated progression of renal dysfunction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources